Viking Therapeutics, Inc.

NASDAQ:VKTX

Biotechnology

Healthcare
$26.17 +1.06%

+$0.32 today

Market cap
$3.34B
Beta
0.68
P/E (TTM)
-7.5
EPS (TTM)
-$4.09
52W Low $22.96High $43.15

Volume 2.87M

Average 2.20M

VKTX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Viking Therapeutics, Inc.NASDAQ: VKTX

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows in line with its trailing trend

Q2 FY2026 weighted avg shares of 115.92M shares rose 3.4% year over year, ahead of the +2.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3.4% holds above the trailing-twelve-month pace of +2.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
115.92M+0.3% QoQ
Last fiscal yearDec 2025
112.67M+3.3% YoY
LTMJun 2026
114.45M+2.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.4%——
1 year+3.3%——
3-year CAGR+13.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
112.67M USD
Year-over-year change
+3.3%
4-year CAGR
+9.9%

Weighted Avg Shares vs competitors

How VKTX compares with its peers on the latest reported figures

  • VKTX's LTM Jun 2026 weighted avg shares of 114.45M shares is the 3rd highest of the 7 companies compared; the peer median is 45.04M shares.
  • Its year-over-year change of +2.5% is the lowest of 6, against a peer median of +17.2%.
  • Over three fiscal years its annual growth of +13.6% compares with a peer median of +36.6%.
VKTX Competitors Peer median
Weighted Avg Shares for VKTX and competitors
Company Period LTM YoY 3-year CAGR
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026119.47M +13.7%+82.0%
KLRAKailera Therapeutics, Inc.FY2025117.95M ——
VKTXViking Therapeutics, Inc.LTM Jun 2026114.45M +2.5%+13.6%
SEPNSepterna, Inc.LTM Sep 202645.24M +9.8%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 202644.83M +33.4%+4.6%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 202625.77M +17.2%+9.4%
VTVTvTv Therapeutics Inc.LTM Mar 20267.87M +30.1%+63.7%
Peer median (excluding VKTX) 45.04M+17.2%+36.6%

Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000431K
Gross Profit0000(431K)
Gross Margin—————
Research & Development44.98M54.23M63.81M101.64M344.96M
Selling, General & Admin10.7M16.12M37.02M49.28M48.39M
Operating Expenses55.68M70.36M100.83M150.92M393.34M
Depreciation & Amortization296K291K292K346K431K
EBITDA(54.68M)(68.52M)(85.52M)(109.52M)(359.15M)
EBITDA Margin—————
Operating Income(55.68M)(70.36M)(100.83M)(150.92M)(393.34M)
Operating Margin—————
Interest Income703K1.59M15.02M40.94M33.7M
Interest Expense18K59K88K94K0
Other Income / Expenses692K1.49M14.93M40.96M33.7M
Income Before Tax(54.99M)(68.87M)(85.9M)(109.96M)(359.64M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(54.99M)(68.87M)(85.9M)(109.96M)(359.64M)
Net Margin—————
EPS (Basic)(0.70)(0.88)(0.91)(1.01)(3.19)
EPS (Diluted)(0.70)(0.88)(0.91)(1.01)(3.19)
Weighted Avg Shares77.2M76.83M94.35M109.04M112.67M
Weighted Avg Shares (Diluted)77.2M76.83M94.35M109.04M112.67M

Viking Therapeutics, Inc.

NASDAQ:VKTX

Intrinsic Alpha fair value

Locked

Current Price

$26.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.